1. Short Communication: Novel Di- and Triselenoesters as Effective Therapeutic Agents Inhibiting Multidrug Resistance Proteins in Breast Cancer Cells.
- Author
-
Radomska D, Czarnomysy R, Marciniec K, Nowakowska J, Domínguez-Álvarez E, and Bielawski K
- Subjects
- Humans, Female, Drug Resistance, Neoplasm drug effects, Cell Line, Tumor, Antineoplastic Agents pharmacology, Antineoplastic Agents chemistry, Organoselenium Compounds pharmacology, Organoselenium Compounds chemistry, Drug Resistance, Multiple drug effects, ATP Binding Cassette Transporter, Subfamily G, Member 2 metabolism, ATP Binding Cassette Transporter, Subfamily G, Member 2 antagonists & inhibitors, MCF-7 Cells, Neoplasm Proteins metabolism, Neoplasm Proteins antagonists & inhibitors, Molecular Docking Simulation, Multidrug Resistance-Associated Proteins metabolism, Multidrug Resistance-Associated Proteins antagonists & inhibitors, Esters pharmacology, Esters chemistry, ATP Binding Cassette Transporter, Subfamily B metabolism, ATP Binding Cassette Transporter, Subfamily B antagonists & inhibitors, Breast Neoplasms drug therapy, Breast Neoplasms metabolism, Breast Neoplasms pathology
- Abstract
Breast cancer has the highest incidence rate among all malignancies worldwide. Its high mortality is mainly related to the occurrence of multidrug resistance, which significantly limits therapeutic options. In this regard, there is an urgent need to develop compounds that would overcome this phenomenon. There are few reports in the literature that selenium compounds can modulate the activity of P-glycoprotein (MDR1). Therefore, we performed in silico studies and evaluated the effects of the novel selenoesters EDAG-1 and EDAG-8 on BCRP, MDR1, and MRP1 resistance proteins in MCF-7 and MDA-MB-231 breast cancer cells. The cytometric analysis showed that the tested compounds (especially EDAG-8) are inhibitors of BCRP, MDR1, and MRP1 efflux pumps (more potent than the reference compounds-novobiocin, verapamil, and MK-571). An in silico study correlates with these results, suggesting that the compound with the lowest binding energy to these transporters (EDAG-8) has a more favorable spatial structure affecting its anticancer activity, making it a promising candidate in the development of a novel anticancer agent for future breast cancer therapy.
- Published
- 2024
- Full Text
- View/download PDF